New research from SNS Insider shows the Regenerative Medicine Market is projected to be valued at $235.98 billion by 2032. Notably, the firm says the market, valued at $32.50 billion in 2023, is experiencing significant growth due to new, innovative therapies for chronic disease and advances in stem cell technology.
These new and innovative therapies look to target chronic disease, cancer, genetic disorders and degenerative conditions.
“In 2023, cell therapy held the dominant share of the regenerative medicine market, accounting for 35% of the total market share. This segment is experiencing robust growth due to its broad applicability in various therapeutic areas such as oncology, musculoskeletal disorders, and neurological diseases.
“The introduction of innovative treatments like CAR-T cell therapy has dramatically advanced the efficacy of cancer therapies, particularly in treating blood cancers such as leukemia and lymphoma,” an excerpt from the report shows.
Of the new research, Peter Choo, Chairman of CytoMed Therapeutics (NASDAQ: GDTC) said, “The prevalence of both chronic, degenerative disease and cancer is, unfortunately on the rise due to an aging world. I agree with SNS’s assessment of the 2032 market value for therapeutics targeting these conditions.
“I would add, however, CytoMed is right now working on CAR T-cell therapies that that target solid cancers. Not only blood cancers like leukemia and lymphoma as the report notes, but an entire host of solid tumors as well.
“For this reason, and of course to assist patients of cancer and degenerative diseases, CytoMed Therapeutics has not only concentrated its efforts on its advanced, off-the-shelf allogenic CAR T-cell cancer therapies, but has acquired the valued assets of cord blood bank CellSafe International.
“This acquisition gives us direct access to rare precious cord blood. Naïve cord blood offers a wide range of opportunities in the fields of regenerative medicine and aging diseases, including auto-immune diseases.
“Further, we were able to acquire CellSafe’s assets at a very reasonable cost. These resources, combined with our scientific expertise, may allow the company to introduce advanced cell technology products into the fast-growing regenerative medicine market,” he said.
For more information on CytoMed Therapeutics and its acquisition of Cord Blood Bank, CellSafe International, visit HERE
Or, to access to the SRS report on Regenerative Medicine, visit HERE
« Trump’s Massive Investment in AI Cancer Vaccines CAR T-Cell Therapy is Very Expensive… But There Are Ways to Reduce Costs »